Identifying genetic pathways that cooperate in leukemogenesis facilitates our understanding of the molecular mechanisms at play. Interferon consensus sequencebinding protein (ICSBP) is a tumor suppressor, whose downregulation cooperates with BCR-ABL and NUP98-TOP1 gene products to accelerate leukemia induction in mouse models. Similarly, Meis1 synergizes with HoxA9 or NUP98-HOX (but not NUP98-TOP1) fusion genes to promote the early onset of leukemia. To investigate whether Icsbp deficiency interacts with Meis1 or its family member Meis3, we transplanted Icsbp À/À bone marrow (BM) cells after transduction with Meis1 or Meis3 retroviral vectors. Here, we show that enforced expression of Meis1 or Meis3 in Icsbp À/À BM cells induces a fatal, invasive myeloproliferative disease. Secondary mutations, such as activation of Mn1, led to the progression to acute myeloid leukemia in a few mice. Interestingly, expression of endogenous Meis1 and Meis3 mRNAs was repressed in the granulocytic progenitor population of Icsbp À/À mice. These results reveal a novel collaboration between Icsbp deficiency and Meis1/Meis3 in the acceleration of chronic myeloid leukemia-like disease. Oncogene (2008) 27, 3865-3869; doi:10.1038/sj.onc.1211043; published online 28 January 2008 Keywords: Meis1; Meis3; Icsbp; AML Interferon consensus sequence-binding protein (ICSBP) (also known as interferon regulatory factor-8) is a transcriptional repressor that acts as a tumor suppressor in myeloid neoplasia. Icsbp-deficient mice exhibit early symptoms of chronic myeloid leukemia (CML) (Holtschke et al., 1996) due to altered sensitivity of early myeloid progenitors to proliferative or apoptotic stimuli (Gabriele et al., 1999; Scheller et al., 1999; Burchert et al., 2004; Schmidt et al., 2004; Zhu et al., 2004) . Downregulation of Icsbp is required for the induction of a CML-like syndrome by BCR-ABL in murine bone marrow (BM) gene transfer experiments (Hao and Ren, 2000) and Icsbp deficiency collaborates with AML-ETO or NUP98-TOP1 leukemia fusion gene products in the progression to acute myeloid leukemia (AML) (Schwieger et al., 2002; Gurevich et al., 2006) . The relevance of these observations in human leukemia has been confirmed by the demonstration that Icsbp is downregulated in 79 and 66% of patients with CML and AML, respectively (Schmidt et al., 1998 (Schmidt et al., , 2001a ).
Meis1, a member of the TALE family of homeodomain genes, is highly expressed in CD34 þ CML cells (Diaz-Blanco et al., 2007) and in AML with intermediate or poor prognosis (Lawrence et al., 1999; Serrano et al., 2006) and its upregulation in known to cooperate with HoxA9 or NUP98-Hox in the induction of AML in mouse models at 100% penetrance (Kroon et al., 1998 (Kroon et al., , 2001 Pineault et al., 2003 Pineault et al., , 2004 . Meis1 was originally identified as a common proviral integration site in AML in BXH-2 mice (Moskow et al., 1995) , which also possess a loss-of-function mutation in the Icsbp gene (Turcotte et al., 2005) . Although Meis1 upregulation has been shown to cooperate with Hox genes, cooperation between Meis1 overexpression and Icsbp deficiency in leukemia progression has not been investigated. Furthermore, although both Meis1 and Meis3 mRNAs are expressed in early myeloid progenitors, the capacity of Meis3 to contribute to leukemogenesis is unknown. The aim of this study was to obtain insight into the role of Meis1/3 in CML and AML progression using the Icsbp-deficient mouse model.
To determine if Meis1 or Meis3 cooperates with Icsbp deficiency to disrupt normal hematopoiesis, Icsbp À/À BM cells were infected with retroviral vectors expressing GFP alone or together with either Meis1 or Meis3 and transplanted into conditioned mice. In contrast to GFP controls, mice receiving BM expressing either Meis1 or Meis3 succumbed within 6 months to a rapid myeloproliferative disorder (MPD) with high penetrance (Figure 1a ). Except for a slightly shorter latency, disease manifestation in mice receiving Meis3-transduced BM was similar to that induced by Meis1. Moribund mice were slightly anemic (median hematocrit 28, range 25-42) and had leukocyte counts in the range of 24-100 Â 10 6 ml
À1
. In all mice succumbing to MPD, 80 to >95% of the non-nucleated cells in peripheral blood (PB) and BM were GFP þ , a surrogate marker for Meis1 or Meis3 (Figure 1b (Nakamura et al., 1996) (primer sequences shown in Supplementary Table S1) or Meis1a cDNA was subcloned into the retroviral vector pMYs-IG. Retroviral infection, transplantation of BM cells, and cytohistochemical and flow cytometrical analyses of peripheral blood (PB) and BM from recipient mice were carried out as previously described (Schwieger et al., 2002) . Recipient mice were C57BL/6J-Ly5.1-Pep3b for Icsbp À/À C57BL/6J-Ly5.2 donor BM cells. All experimental procedures with mice were pre-approved by the ethical committee of each institute. Analysis of blood smears demonstrated that the increased leukocyte counts were due to granulocytosis (Figure 1d ). The aggressive nature of the MPD was demonstrated by histological analysis of various organs. The BM was hypercellular with little or absent erythropoiesis and infiltration of the surrounding musculature and mediastinal fat tissue was observed in two of four mice analyzed (Figure 1e ). Spleens were slightly enlarged due to hyperplasia of the red pulp, involving both granulopoiesis and erythropoiesis (expulsed from BM). In most spleens analyzed, the white pulp was partially or completely displaced by the granulocytic hyperplasia (Figure 1f ). Granulocytic infiltrates were also observed, to different degrees, in the kidney, liver and lung (Figures 1g-i) . Death could be attributed to compromised breathing and/or hepatic failure. Enforced expression of Meis1 or Meis3 in Icsbp þ / þ BM cells with similar transduction efficiency (45-57%) did not induce disease or significantly alter the frequency of myeloid cell population in PB at 9 months after transplantation (n ¼ 7-9) (data not shown). Taken together, these results show that enforced expression of Meis1 or Meis3 synergizes with Icsbp deficiency to induce an accelerated MPD. Notably, the disease is similar to that observed in wild-type BM transduced with Meis1 fused to a dominant activation domain (Wang et al., 2006) , suggesting that Icsbp deficiency circumvents the necessity of a strongly activating Meis1 protein.
In mice succumbing to the Meis-induced disease at later stages (>80 days), increasing levels of immature myeloblastic forms were present in the PB and BM (Figure 1c , middle) and two mice were diagnosed with AML (>25% myeloblasts in BM). Southern blot analysis designed to detect proviral integration sites in splenic or liver DNA from Meis3-transduced mice revealed that the two AML tumors were predominantly clonal, whereas MPD was a polyclonal disease (Figure 2a) . Furthermore, the MPD phenotype was not transplantable in secondary BM recipient mice (data not shown). These data suggest that the progression to AML of Meis3-transduced MPD mice is the result of secondary mutations. Multiple integration sites in the AML tumors were isolated by ligase-mediated PCR (Schmidt et al., 2001b) . In one tumor, viral integration occurred in the first intron of Mn1 gene (Figure 2b ). Similar retroviral integrations have recently been shown to collaborate with NUP98-HoxD13 in leukemic transformation (Slape et al., 2007) . No integration sites were found in the HoxA9 locus. Thus, AML progression of Meis1/Meis3-transduced Icsbp À/À BM cells can occur in collaboration with Hox-cooperating genes.
Icsbp À/À mice produce two to threefold more granulocytes in PB and twofold more white blood cells in BM when compared to control C57BL/6 mice; however, the level of common myeloid, granulocyte-monocyte or megakaryocyte-erythroid progenitors (CMP, GMP and MEP, respectively) has not been previously examined. Consistent with increased granulopoiesis in these mice, a significant increase in GMP levels was observed in
Icsbp
À/À BM, coincident with a relative decrease in the frequency of CMP or MEP (Supplementary Figures S1a  and b) . As Meis1 and Meis3 further enhance granulopoiesis in Icsbp-deficient but not wild-type mice, we investigated the expression of Meis family members in BM myeloid precursor populations and peripheral granulocytes of C57BL/6 (Icsbp þ / þ ), Icsbp þ /À and Icsbp À/À mice by real-time reverse transcription-PCR. As Icsbp À/À mice produce mRNA carrying the nonsense mutation, it is possible to detect Icsbp mRNA in these mice (Holtschke et al., 1996) . Gene expression of Meis1a, Meis1b (an alternative splicing form of Meis1 gene) and Meis3 mRNAs was enhanced in CMP of Icsbp À/À mice (Figure 3a) . In sharp contrast, all of these mRNAs were strikingly reduced in the GMP, MEP and PB CD11b þ /Gr1 þ fractions of Icsbp À/À mice (Figures  3b-d) . Meis2 transcripts were barely detectable in any of these fractions (data not shown). Expression levels of Meis1a and Meis1b mRNAs were decreased in both GMP and MEP of heterozygous Icsbp þ /À mice, (Figure 3d ), the amount of Meis1a/Meis1b transcripts in this population was extremely small compared to that in CMP, GMP and MEP (Supplementary Figure S2) . There exists one PRDI consensus sequence (5 0 -TCACTT-3 0 ) for ICSBP binding (from À683 to À678) and four potential interferon-stimulated response elements between À596 and À437 in the upstream region of the transcriptional initiation site of the murine Meis1 gene. Therefore, Meis1 gene expression may be normally regulated by ICSBP, either as a repressor in CMP or an activator in GMP and MEP, although further investigation is required to prove this possibility. Whatever the mechanism, the observed downregulation of Meis1 in the GMP of Icsbp À/À mice may prevent a fatal preleukemic myeloproliferation in these mice.
The Icsbp deficiency provides an important 'first hit' in multistep leukemogenesis (Kelly and Gilliland, 2002) , providing a cellular environment for secondary events to manifest into either an accelerated CML or an overt AML. Interestingly, the leukemic phenotype induced by NUP98-TOP1 and Icsbp deficiency (Gurevich et al., 2006 ) is similar to NUP98-Hox and Meis1 (Kroon et al., 2001) , whereas Meis1 cannot synergize with NUP98-TOP1 (Gurevich et al., 2006) . These facts suggest that the pathways activated by Icsbp deficiency and Meis1 are complementary but not overlapping. The synergy between Icsbp deficiency and Meis1/Meis3 reported here further supports the distinct roles of these two leukemiaassociated genes in leukemogenesis. Supplementary Table S1 . Gene expression was normalized to GAPDH mRNA levels and expressed as a relative amount to that of Icsbp þ / þ mice. Values are the means±s.e. *Po0.01; **Po0.05 compared to Icsbp þ / þ mice (n ¼ 3). ND, not detectable.
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